First CVGBM Glioblastoma Vaccine enters Phase 1 Trials
Time to read: 01:48. Glioblastoma (GBM), a highly aggressive brain tumour, is the focus of CureVac’s first investigational cancer vaccine, CVGBM
Source: FDA
Feature
Text
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
Time to read: 01:29. On 15 November 2024, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), the first menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukaemia with lysine methyltransferase 2A gene (KMT2A) translocation in adult and paediatric patients aged one year and older.
Source: FDA Press Release
Text
